---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-21-020423"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2021-08-18T23:59:59+00:00"
generated_at: "2026-06-29T09:11:20.268808+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# KemPharm appoints Tamara A. Seymour to board and audit committee chair

## Summary
- Appointment effective August 18, 2021; Seymour becomes Class I director, term expiring at 2022 annual meeting.
- Seymour brings over 30 years life sciences experience, including CFO roles at several public and private biotech firms.
- Initial grant of 22,500 stock options vesting in three equal annual installments under 2014 equity plan.
- Annual retainers: $35,000 for board service and $22,500 for audit committee chair.
- CEO notes appointment comes at 'important phase' as KemPharm seeks organic and external growth opportunities.

## SEC filing metadata
- accession: 0001437749-21-020423
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2021-08-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774921020423/0001437749-21-020423-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774921020423/kmph20210817_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-21-020423
- JSON: https://secwatch.observer/filing/0001437749-21-020423.json
- Plain text: https://secwatch.observer/filing/0001437749-21-020423.txt

## Key facts
- Executive change
  Tamara A. Seymour was appointed as Director and Chair of the Audit Committee at ZEVRA THERAPEUTICS, INC..
  - Action: appointed
  - Role: Director and Chair of the Audit Committee
  source text: the board of directors (the “Board”) of KemPharm, Inc. (the “Company”) appointed Tamara A. Seymour to serve as a director of the Company and as the chair of the Company’s audit committee.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774921020423/0001437749-21-020423-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.